An infant exposed in utero to valproic acid was born with multiple congenital malformations, including duodenal atresia, lumbar vertebral fusion, thoracolumbar scoliosis, renal abnormalities, diastasis recti abdominis, depigmentation of the eye brows, and a large hemangioma. The child had neonatal hyperbilirubinemia and postnatal growth deficiency. This case report is an addition to the literature im plicating valproic acid as a human teratogen.
Get full access to this article
View all access options for this article.
References
1.
Browne TRValproic acid. N Engl J Med1980;302: 661-6.
2.
Hanson JW, Smith DWThe fetal hydantoin syndrome. J Pediatr1975 ;87:285-90.
Bailey CJ, Pool RW, Poskitt EM, et al. Valproic acid and fetal abnormality. Br Med J1983;286:190.
5.
Bjerkedal T. , Czeizel A., Goujard J., et al. Valproic acid and spina bifida. Lancet1982∞(8307): 1096.
6.
Centers for Disease Control.Valproic acid and spina bifida: a preliminary report—France. MMWR October29, 1982 ;31:565-6.
7.
Whittle BAPre-clinical teratological studies on sodium valproate (Epilim) and other anticonvulsants. In: Legg NJ, ed. Clinical and pharmacological aspects of sodium valproate (Epilim) in the treatment of epilepsy. Turnbridge Wells, England: MSC Consultants, 1976:105-11.
8.
Pinder RM, Brodgen RN, Speight TM, et al. Sodium valproate: a review of its pharmacological properties and therapeutic efficacy in epilepsy. Drugs1977;13:81-123.
9.
Nau H., Rating D., Koch S., et al. Valproic acid and its metabolites: placental transfer, neonatal pharmacokinetics, transfer via mother's milk and clinical status in neonates of epileptic mothers. J Pharm Exp Ther1981 ;219:768-77.
